BRIEF—Oxford Biomedica expands deal with Cabaletta Bio

UK gene and cell therapy group Oxford Biomedica says that it has expanded its license and supply agreement (LSA) with US biotech Cabaletta Bio, which is focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases.

This follows on from the LSA announced in  January 2022 and adds CD19 as a new target.

Cabaletta Bio has received two investigational new drug (IND) clearances to date for CABA-201 and plans to initiate a Phase I/II clinical trial for patients with systemic lupus erythematosus and lupus nephritis and a separate Phase I/II clinical trial for patients with myositis.

Under the terms of the expanded agreement, Oxford Biomedica will receive an undisclosed upfront payment, and will be eligible for additional payments relating to the development and manufacture of lentiviral vectors for use in clinical trials.

The company will also receive certain development and regulatory milestone payments and an undisclosed royalty on net sales of products that utilise the company's LentiVector platform.